Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775928 | 0.94 | GNAI3 (0.42) | ATMGNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL19309525 | 0.90 | ITGB3 (0.41) | ITGB3ITGA2BGAATPSAB1TPSD1 | |
| SCHEMBL21168191 | 0.81 | ATM (0.55) | ATMITGB3ITGA2B | |
| SCHEMBL12284392 | 0.78 | PRMT1 (0.44) | ATMGNAI3GNAI1ITGB3ITGA2B | |
| SCHEMBL4040370 | 0.77 | TPSAB1 (0.40) | ATMITGB3ITGA2BGAATPSAB1 | |
| SCHEMBL13974287 | 0.77 | GNAI3 (0.44) | ATMGNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL24322731 | 0.77 | DPP8 (0.38) | ITGB3ITGA2B | |
| SCHEMBL27336659 | 0.76 | GNAI3 (0.41) | ATMGNAI3GNAO1GNAI1TPSAB1 | |
| SCHEMBL14980274 | 0.76 | GNAI3 (0.44) | GNAI3GNAO1GNAI1TPSAB1TPSD1 | |
| SCHEMBL9415769 | 0.75 | GNAI3 (0.56) | ATMGNAI3GNAO1GNAI1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024499-B1 | OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES | SAREPTA THERAPEUTICS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2735568-B1 | Oligonucleotide analogs having cationic intersubunit linkages | AVI BIOPHARMA INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2735568-A1 | Oligonucleotide analogs having cationic intersubunit linkages | AVI BioPharma, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-7943762-B2 | Oligonucleotide analogs having cationic intersubunit linkages | AVI BIOPHARMA, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090088562-A1 | Oligonucleotide analogs having cationic intersubunit linkages | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2009-04-02 | — | — | US | disclosed |
| EP-2024499-A2 | OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES | Avi Biopharma, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008036127-A2 | OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES | AVI BIOPHARMA, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088562-A1 | Oligonucleotide analogs having cationic intersubunit linkages | SLC38A7, SLC43A3, SLC28A3 | ATM 4331/4885GNAI3 3213/4885GNAO1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.